If you’ve done any research into peptide therapy, you’ve almost certainly encountered the terms GLP-1, semaglutide, tirzepatide, and the brand names Wegovy, Ozempic, Mounjaro, and Zepbound. The interest — and the confusion — around these compounds is understandable given how rapidly the field has evolved. Here’s a clear overview of what GLP-1 receptor agonists are, how they work, and what the clinical picture actually looks like.
What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It’s a naturally occurring hormone — technically a peptide — produced primarily in the small intestine in response to food intake. When you eat, GLP-1 is released into the bloodstream and triggers several important physiological responses:
- Stimulates insulin secretion from the pancreas (in a glucose-dependent manner)
- Suppresses glucagon release, reducing glucose output from the liver
- Slows gastric emptying, which extends the sense of fullness after eating
- Acts on receptors in the brain to reduce appetite signaling
The net effect is improved blood glucose regulation and reduced caloric intake — which is why GLP-1 receptor agonists have been studied so extensively for type 2 diabetes and metabolic health.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are synthetic compounds designed to mimic or enhance the action of natural GLP-1. Unlike the natural hormone, which is rapidly broken down in the body, these pharmaceutical agents are engineered to have a longer half-life — meaning they remain active for hours to weeks depending on the formulation.
Semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (active in Mounjaro and Zepbound) are the most widely discussed. Tirzepatide is sometimes called a “dual agonist” because it acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing a compounded metabolic effect.
What Does the Research Show?
The clinical trial data on GLP-1 receptor agonists has been substantial enough to genuinely shift medical thinking around metabolic disease. Key findings include:
Weight reduction: In the STEP trial program, semaglutide at 2.4mg weekly produced mean weight loss of approximately 14–17% of body weight in participants with obesity — significantly greater than any previous pharmacological intervention. Tirzepatide data showed even more pronounced reductions in some cohorts.
Cardiovascular outcomes: The SELECT trial (2023) demonstrated that semaglutide reduced major cardiovascular events by 20% in a high-risk population — a finding that expanded its clinical relevance well beyond glucose control.
Metabolic markers: Beyond weight and cardiovascular risk, studies show improvements in blood pressure, triglycerides, HbA1c, liver fat content, and inflammatory markers.
Who Are Appropriate Candidates?
GLP-1 receptor agonists are prescription medications. In clinical practice, they are typically considered for patients with:
- Type 2 diabetes requiring glycemic control
- Obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
- Elevated cardiovascular risk with evidence-based need for pharmacological support
Candidacy is determined by a licensed physician following a clinical evaluation. Contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, among others. Patients with a history of pancreatitis are typically evaluated carefully before initiating therapy.
Branded vs. Compounded: What’s the Difference?
There’s been significant public discussion about compounded versions of semaglutide and tirzepatide, which became more widely available during periods of brand-name drug shortage. Compounded versions are prepared by licensed 503A or 503B pharmacies and dispensed under physician prescription.
It’s important to understand that compounded medications are not FDA-approved (the compounding process itself, not the active ingredient, is what differs). However, when compounded by reputable licensed pharmacies with proper purity verification, they represent a legitimate and legally sanctioned alternative to branded medications — particularly when brand-name supply is constrained or cost is prohibitive for a patient.
Your prescribing physician will evaluate which formulation is most appropriate given your clinical situation, insurance coverage, and current market availability.
What to Expect If You’re Starting Therapy
GLP-1 therapy is not an overnight solution. Typical titration schedules start at a low dose and increase gradually over weeks to months, allowing the body to adapt and reducing the likelihood of gastrointestinal side effects (nausea, vomiting, and constipation are the most commonly reported).
Most patients begin to notice appetite changes within the first few weeks. Meaningful weight reduction typically becomes apparent over 3–6 months of consistent use. Regular physician check-ins throughout therapy allow for dose adjustments, side effect management, and progress monitoring.
The Clinical Bottom Line
GLP-1 receptor agonists represent one of the most clinically significant pharmacological developments in metabolic medicine in decades. They are not supplements, not peptides in the traditional sense of how that term is used in longevity and performance medicine, and not a substitute for lifestyle intervention — but for appropriate patients under physician supervision, the evidence supporting their use is substantial.
If you’re interested in understanding whether GLP-1 therapy is appropriate for your situation, a licensed physician intake is the right first step.
Leave a Reply